← Back to Clinical Trials
Recruiting NCT05562310

NCT05562310 Phenylalanine, Methionine and Histidine Requirements in TPN Fed Neonates

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05562310
Status Recruiting
Phase
Sponsor The Hospital for Sick Children
Condition Stable Neonates
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-04-02
Primary Completion 2026-09-02

Eligibility & Interventions

Sex All sexes
Min Age 1 Day
Max Age 28 Days
Study Type INTERVENTIONAL
Interventions
Total parenteral nutrition (TPN). This is total nutrition provided by central vein.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-04-02 with a primary completion date of 2026-09-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a single center project assessing the requirements for three essential amino acids in TPN fed neonates. Using the Carbon Oxidation method (indicator amino oxidation and direct amino acid oxidation method), the investigators will determine the requirement of each of the 3 amino acids. The investigators will first determine the requirement for Phenylalanine, then Methionine and finally Histidine. The investigators will recruit 18 - 20 babies per amino acid study. Breath and urine samples will be collected to determine the oxidation of the indicator amino acid. The response of the indicator amino acid to changes in intake of the test amino acid (phenylalanine, methionine, and histidine) will be analyzed by bi-phase linear mixed effect model to determine the breakpoint or mean requirement for each amino acid. It is hypothesized that the requirement for phenylalanine, methionine and histidine will be at least 50% lower than what is currently available in commercial amino acids solutions used for TPN feeding of neonates.

Eligibility Criteria

Inclusion Criteria: 1. Stable preterm babies that are growing and fully TPN fed (at least 90% of calories and protein). 2. TPN providing adequate calories and protein as determined by attending physician and dietitian. 3. Babies born ≥ 28 weeks gestation, 4. ≤ 28 days chronological age at the time of the study, 5. Birth weight and length appropriate for gestational age, 6. Medically stable as determined by normal blood results and lack of a fever or infection, 7. At least 3 days after surgery, if the baby had a surgery. Exclusion Criteria: 1. Babies on mechanical ventilation, on low flow oxygen and CPAP. 2. Small for gestational age, 3. On medications known to affect protein and amino acid metabolism, 4. Documented infection, fever 5. Unstable medical condition 6. Receiving enteral feeding providing \> 10% of protein intake.

Contact & Investigator

Central Contact

Glenda Courtney-Martin

✉ glenda.courtney-martin@sickkids.ca

📞 4168135744

Frequently Asked Questions

Who can join the NCT05562310 clinical trial?

This trial is open to participants of all sexes, aged 1 Day or older, up to 28 Days, studying Stable Neonates. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05562310 currently recruiting?

Yes, NCT05562310 is actively recruiting participants. Contact the research team at glenda.courtney-martin@sickkids.ca for enrollment information.

Where is the NCT05562310 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT05562310 clinical trial?

NCT05562310 is sponsored by The Hospital for Sick Children. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology